Octave Bioscience Announces $35M Series C Financing to Accelerate Commercial Momentum
MENLO PARK, Calif.–(BUSINESS WIRE)–Octave Bioscience, Inc., a commercial stage precision care company that is pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announces the close of its $35.6 million…